Immunogenic cell death-related classifications in breast cancer identify precise immunotherapy biomarkers and enable prognostic stratification.

Wang, Xue; Huang, Hailiang; Liu, Xijian; Li, Jiuwei; Wang, Lu; Li, Ling; Li, Yaxing; Han, Tao

Wang, Xue; Huang, Hailiang; Liu, Xijian; Li, Jiuwei; Wang, Lu; Li, Ling; Li, Yaxing; Han, Tao.

Afiliación

Wang X; Pharmacology of Traditional Chinese Medical Formulae, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Huang H; College of Rehabilitation Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Liu X; Pharmacology of Traditional Chinese Medical Formulae, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Li J; College of Medical, Shandong University of Traditional Chinese Medicine, Jinan, China.
Wang L; Office of Academic Research, Shandong University of Traditional Chinese Medicine, Jinan, China.
Li L; Pharmacology of Traditional Chinese Medical Formulae, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Li Y; Pharmacology of Traditional Chinese Medical Formulae, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Han T; Pharmacology of Traditional Chinese Medical Formulae, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.

Front Genet ; 13: 1052720, 2022.

Article en En | MEDLINE | ID: mdl-36437951

Palabras clave

breast cancer; immunogenic cell death; immunotherapy; risk prognosis; tumor microenvironment

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Genet Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google